Ocuphire Pharma Investor Day Presentation Deck

APX3330 History and Ref-1 Inhibition Mechanism DME Ref-1 Involved in Multiple Key Pathways that Contribute to Diabetic Retinopathy and DME DR 12 Mechanism of Action - Ref-1 Inhibition Нурохіа Ref-1 HIF-1a VEGF (Signaling Cascade) Anti-VEGF APX3330 Neovascularization Lucentis® EYLEAⓇ Logsdon et al (2018), Li et al (2014). Inflammation ↓ Ref-1 NF-kB TNF-a Chemokines Other Growth Factors (Signaling Cascade) Steroids ● • Ref-1 (reduction-oxidation effector factor-1) is a novel target discovered by Dr. Mark R. Kelley at Indiana University School of Medicine ● ● APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of Ref-1 APX3330 previously developed by Eisai for multiple hepatic inflammatory indications and later by Apexian for advanced solid tumors Similar oncology origin as approved anti-VEGFs • MOA uniquely decreases both abnormal angiogenesis and inflammation by blocking pathways downstream of Ref-1 Ocuphire PHARMA

View entire presentation